Exploratory Study Investigating Urodynamic Parameters During Catheterisation
NCT ID: NCT03337048
Last Updated: 2024-08-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2017-11-30
2018-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bladder Scan of Residual Urine With New Catheter
NCT01048541
Evaluation of Residual Urine After Intermittent Catheterisation
NCT00324233
Intermittent Catheterisation on the Bladder Mucosa of Healthy Volunteers With a Prototype Micro Hole Zone Catheter
NCT05224544
Detrusor Activity Recovery in Acute Traumatic Spinal Cord Injuries
NCT05207826
Connected Catheter Clinical Feasibility Study( CFS)
NCT03405285
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The healthy volunteers included into the study will have an information visit and three study visits - an inclusion visit (visit 0), a visit 1 measuring endpoints while spontaneous voiding of the bladder (0-7 days after visit 0) followed by a visit 2 measuring endpoints while emptying the bladder using a standard IC (4-15 days after visit 1). (Visit 0 and visit 1 can be the same day).
The subjects with SCI and enlarged prostate will have an information visit and two study visits. - an inclusion visit (visit 0) where a urine culture is analysed and prophylactic antibiotic is prescribed per the result of the analysis. (Most IC users have bacteria in the urine and to decrease the risk of acquiring a urinary tract infection from the urodynamic examination, urine cultures are performed and prophylactic antibiotics will be prescribed per the result). The second visit (visit 1) is conducted while the patient is on antibiotic treatment measuring all endpoints while emptying the bladder with a standard IC (4-15 days after visit 0 while subject is on prophylaxis antibiotics).
The investigation is conducted at one site and is an explorative study, estimated to last eight (8) months.
Due to the explorative nature of the investigation, no primary endpoint is defined but explorative endpoints are divided into three categories dependent on their relation to bladder, urethra or urine.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Measurement of endpoints
In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter.
In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter.
SpeediCath
SpeediCath is a standard intermittent catheter that is on the market.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SpeediCath
SpeediCath is a standard intermittent catheter that is on the market.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be at least 18 years of age and have full legal capacity
3. Be male
4. For healthy volunteers: Willing to comply with not using analgesics up to 24 hours prior to study visit
5. For healthy volunteers: Negative urine multistix (leukocytes and nitrite), or if positive, subsequent negative for bacterial growth in urine culture
6. For SCI and BPH patients: Use intermittent catheter daily and have used intermittent catheters for at least 2 months
Exclusion Criteria
2. Participate in other clinical investigations related to urinary tract system during this investigation (Inclusion → termination)
3. For healthy volunteers: Abnormalities, diseases or surgical procedures performed in the lower urinary tract
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Coloplast A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nazarena Mazarro
Role: STUDY_DIRECTOR
Vice president Medical Affairs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Urology, Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP277
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.